奥希替尼改善EGFR突变NSCLC软脑膜转移患者总生存且不受T790M状态影响
该回顾性研究纳入2008年10月至2019年10月共351例细胞学确诊软脑膜转移的EGFR突变NSCLC患者,按是否接受奥希替尼及T790M状态分析总生存。结果显示奥希替尼治疗组中位OS为17.0个月,显著优于未治疗组的5.5个月(HR 0.36,95%CI 0.28-0.47,P<0.001),且不受T790M突变状态影响。
要点
- 奥希替尼治疗组中位OS 17.0个月,未治疗组5.5个月,HR 0.36。
- T790M突变状态与中位OS无关(10.1 vs 9.0个月,P=0.936)。
- 奥希替尼疗效优于第一/二代EGFR-TKI(中位OS 8.7个月)。
核心结论
- 奥希替尼是EGFR突变NSCLC伴软脑膜转移的有前景治疗选择,无论T790M突变状态如何。
研究设计与样本
- 回顾性分析2008年10月至2019年10月细胞学确诊软脑膜转移的EGFR突变NSCLC患者,共351例。
- 按是否接受奥希替尼治疗及T790M突变状态分组,总生存定义为从软脑膜转移诊断至死亡的时间。
主要发现
- 351例患者总体中位OS为8.1个月(95%CI 7.2-9.0)。
- 197例检测T790M,88例阳性;110例在软脑膜转移后接受奥希替尼治疗。
- T790M突变状态与中位OS无关:阳性10.1个月(95%CI 4.31-15.82)vs 阴性9.0个月(95%CI 6.81-11.21),P=0.936。
- 奥希替尼治疗组中位OS为17.0个月(95%CI 15.13-18.94),未治疗组为5.5个月(95%CI 4.34-6.63),HR 0.36(95%CI 0.28-0.47),P<0.001,且不受T790M状态影响。
- 奥希替尼治疗组中位OS也长于从未接受奥希替尼但接受第一/二代EGFR-TKI者的8.7个月(95%CI 7.01-10.39)。
临床怎么用
- 对于EGFR突变NSCLC伴软脑膜转移患者,可考虑使用奥希替尼,无需依赖T790M突变状态选择。
局限性
- 本研究为回顾性分析,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, efficiently penetrates the blood-brain barrier. This study explored whether treatment with osimertinib leads to improved overall survival (OS) for patients with EGFR-mutated NSCLC with leptomeningeal metastases (LM) compared with those not treated with osimertinib. METHODS: From October 2008 to October 2019, patients with EGFR-mutated NSCLC and cytologically confirmed LM were retrospectively analyzed for OS according to osimertinib treatment and T790M mutational status. The OS was defined as the time from the diagnosis of LM to death. RESULTS: For the 351 patients with LM included in the analysis, the median OS (mOS) was 8.1 months (95% confidence interval [CI]: 7.2-9.0). T790M mutation was detected in 88 of 197 patients tested, and a total of 110 patients were treated with osimertinib after LM. No difference in mOS according to T790M mutational status (10.1 mo [95% CI: 4.31-15.82] versus 9.0 [95% CI: 6.81-11.21], p = 0.936) was found. Nevertheless, patients treated with osimertinib had a superior OS of 17.0 months (95% CI: 15.13-18.94) compared with those not treated with osimertinib who had a mOS of 5.5 months (95% CI: 4.34-6.63), regardless of T790M mutational status (hazard ratio: 0.36 [95% CI: 0.28-0.47], p < 0.001). This was also considerably longer even than the mOS of 8.7 months (95% CI: 7.01-10.39) of those who were never treated with osimertinib but had first- or second-generation EGFR tyrosine kinase inhibitors. CONCLUSIONS: Osimertinib is a promising treatment option for EGFR-mutated NSCLC with LM regardless of T790M mutational status.
引用
- Lee J, Choi Y, Han J, et al. Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. J Thorac Oncol. 2020. PMID: 32652216. doi:10.1016/j.jtho.2020.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。